David Ansell to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications David Ansell has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
0.677
-
Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis. 2018 01; 268:99-107.
Score: 0.540
-
Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis. 2018 04; 271:120-127.
Score: 0.137